SpringWorks Therapeutics, Inc. - common stock (SWTX)
37.50
+0.27 (0.73%)
Springworks Therapeutics is a biopharmaceutical company dedicated to developing innovative therapies for underserved patient populations, particularly in the field of rare diseases and oncology
The company utilizes its proprietary drug development platform to identify and advance novel treatments, focusing on precision medicine approaches. By leveraging its expertise in biomarker-driven strategies, Springworks aims to bring transformative therapeutics to market, addressing significant unmet medical needs and improving the quality of life for patients dealing with complex health challenges.
SWTX stock results show that SpringWorks Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Shares of SpringWorks Therapeutics, Inc. (NASDAQSWTX) surged in pre-market trading after the company reported the FDA approval of OGSIVEO (nirogacestat) as the first and only treatment for adults with desmoid tumors. SpringWorks Therapeutics shares rose 14.4% to $23.77 in pre-market trading
The FDA approved SpringWorks Therapeutics Inc's (NASDAQSWTX) Ogsiveo (nirogacestat), an oral gamma-secretase inhibitor, for adult patients with progressing desmoid tumors who
SpringWorks Therapeutics Inc (NASDAQSWTX) released topline results from its Phase 2b ReNeu trial evaluating mirdametinib, an investigational MEK inhibitor, in pediatric and adult patients with NF1-associated
In March, the FDA issued SpringWorks Therapeutics Inc (NASDAQSWTX) with a Form 483 letter due to a failure to ensure that the analysis of an exploratory endpoint in the Phase 3 DeFi trial, which evaluated nirogacestat for the treatment of desmoid tumor (DT) patients that have experienced progres
